Research
Hormonal
Metformin use significantly alters gut microbiota composition and contributes to its beneficial effects on glucose homeostasis, acting as a strong confounder in metagenomic studies of T2DM.
If you take Metformin for diabetes, your gut bacteria are likely different from non-users. This is a known effect of the drug and may contribute to its benefits. Do not stop taking prescribed medication to 'fix' your microbiota naturally without consulting your doctor.
GoodSupportsMEDIUM confidence
metformin is a strong confounding factor in metagenomic analysis... metformin-treated subjects had significantly altered gut microbiome composition compared to patients receiving placebo
Why this rating
Based on specific human trials cited (double-blind, placebo-controlled) showing significant alteration.
Source
Evaluating Causality of Gut Microbiota in Obesity and Diabetes in Humans
Abraham S. Meijnikman et al. · Endocrine Reviews · 2017
DOI 10.1210/er.2017-00192
narrative_reviewCited 278×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Dietary interventions can rapidly alter gut microbiota composition and function, but long-term changes require sustained dietary habits, and individual response varies significantly based on baseline microbial richness.Good
- Gut microbiota composition and metabolite production are associated with obesity and type 2 diabetes, but current human evidence is largely associative and causality remains unproven due to scarcity of intervention data.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →